Trivalent IL-5-HSA bispecific Nb (Novamab Biopharmaceuticals)

IL-5/HSA三价双特异性抗体（洛启生物）

Report date: 2023/03/01 16:29:11

Base Information

Drug NameTrivalent IL-5-HSA bispecific Nb (Novamab Biopharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Serum albuminInterleukin-5 inhibitors

TargetsSerum albuminInterleukin-5

Therapy Area/IndicationsAsthma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd

Inactive CompaniesN/A

Active IndicationsAsthma

Inactive IndicationsN/A

Other Information

ATC CodeN/A